{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:23:26Z","timestamp":1773872606178,"version":"3.50.1"},"reference-count":25,"publisher":"Medical Association of Nippon Medical School","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2023,8,25]]},"DOI":"10.1272\/jnms.jnms.2023_90-502","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T22:09:23Z","timestamp":1653862163000},"page":"346-350","source":"Crossref","is-referenced-by-count":1,"title":["Primary Central Nervous System Lymphoma in a Patient with Down Syndrome"],"prefix":"10.1272","volume":"90","author":[{"given":"Ami","family":"Shibata","sequence":"first","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Nippon Medical School Tama Nagayama Hospital"},{"name":"Department of Emergency and Critical Care Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgical Surgery, Nippon Medical School"},{"name":"Department of Neurosurgery for Community Health, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Yokobori","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Neurosurgical Surgery, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. O&apos;Leary L, Hughes-McCormack L, Dunn K, Cooper SA. Early death and causes of death of people with Down syndrome: a systematic review. J Appl Res Intellect Disabil. 2018;31 (5):687-708.","DOI":"10.1111\/jar.12446"},{"key":"2","unstructured":"2. O&apos;Nuall\u00e1in S, Flanagan O, Raffat I, Avalos G, Dineen B. The prevalence of Down syndrome in County Galway. Ir Med J. 2007;100 (1):329-31."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Asim A, Kumar A, Muthuswamy S, Jain S, Agarwal S. &quot;Down syndrome: an insight of the disease&quot;. J Biomed Sci. 2015;22 (1):41.","DOI":"10.1186\/s12929-015-0138-y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lee P, Bhansali R, Izraeli S, Hijiya N, Crispino JD. The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome. Leukemia. 2016;30 (9):1816-23.","DOI":"10.1038\/leu.2016.164"},{"key":"5","unstructured":"5. Mateos MK, Barbaric D, Byatt SA, Sutton R, Marshall GM. Down syndrome and leukemia: insights into leukemogenesis and translational targets. Transl Pediatr. 2015;4 (2):76-92."},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Satg\u00e9 D, Monteil P, Sasco AJ, et al. Aspects of intracranial and spinal tumors in patients with Down syndrome and report of a rapidly progressing Grade 2 astrocytoma. Cancer. 2001;91 (8):1458-66.","DOI":"10.1002\/1097-0142(20010415)91:8<1458::AID-CNCR1153>3.0.CO;2-B"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Satg\u00e9 D, Stiller CA, Rutkowski S, et al. A very rare cancer in Down syndrome: medulloblastoma. Epidemiological data from 13 countries. J Neurooncol. 2013;112 (1):107-14.","DOI":"10.1007\/s11060-012-1041-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Alexandrov PN, Percy ME, Lukiw WJ. Chromosome 21-Encoded microRNAs (mRNAs): impact on Down&apos;s syndrome and trisomy-21 linked disease. Cell Mol Neurobiol. 2018;38 (3):769-74.","DOI":"10.1007\/s10571-017-0514-0"},{"key":"9","unstructured":"9. Nakamaki T. [Recent advances in the treatment of primary central nervous system lymphoma]. Brain Nerve. 2014;66 (8):969-79. Japanese."},{"key":"10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12885-016-2311-4","volume":"16","author":"E Schorb","year":"2016","unstructured":"10. Schorb E, Finke J, Ferreri AJ, et al. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix). BMC Cancer. 2016;16:282.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 2002;95 (7):1504-10.","DOI":"10.1002\/cncr.10851"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Doucet S, Kumthekar P, Raizer J. Primary central nervous system lymphoma. Curr Treat Options Oncol. 2013;14 (2):185-97.","DOI":"10.1007\/s11864-013-0227-7"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. L\u00f6w S, Han CH, Batchelor TT. Primary central nervous system lymphoma. Ther Adv Neurol Disord. 2018;11:1756286418793562.","DOI":"10.1177\/1756286418793562"},{"key":"14","unstructured":"14. Lukas RV, Stupp R, Gondi V, Raizer JJ. Primary central nervous system lymphoma-PART 1: epidemiology, diagnosis, staging, and prognosis. Oncology (Williston Park). 2018;32 (1):17-22."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kaczorowska N, Kaczorowski K, Laskowska J, Mikulewicz M. Down syndrome as a cause of abnormalities in the craniofacial region: a systematic literature review. Adv Clin Exp Med. 2019;28 (11):1587-92.","DOI":"10.17219\/acem\/112785"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tsou AY, Bulova P, Capone G, et al. Medical care of adults with Down syndrome: a clinical guideline. JAMA. 2020;324 (15):1543-56.","DOI":"10.1001\/jama.2020.17024"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Satg\u00e9 D, Sommelet D, Geneix A, Nishi M, Malet P, Vekemans M. A tumor profile in Down syndrome. Am J Med Genet. 1998;78 (3):207-16.","DOI":"10.1002\/(SICI)1096-8628(19980707)78:3<207::AID-AJMG1>3.0.CO;2-M"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ehara H, Ohno K, Ito H. Benign and malignant tumors in Down syndrome: analysis of the 1514 autopsied cases in Japan. Pediatr Int. 2011;53 (1):72-7.","DOI":"10.1111\/j.1442-200X.2010.03189.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Mukasa A. Genome medicine for brain tumors: current status and future perspectives. Neurol Med Chir (Tokyo). 2020;60 (11):531-42.","DOI":"10.2176\/nmc.ra.2020-0175"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tamura R, Toda M. Historic overview of genetic engineering technologies for human gene therapy. Neurol Med Chir (Tokyo). 2020;60 (10):483-91.","DOI":"10.2176\/nmc.ra.2020-0049"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Narita Y, Nagane M, Mishima K, et al. Phase I\/II study of tirabrutinib, a second-generation Bruton&apos;s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma. Neuro Oncol. 2021;23 (1):122-33.","DOI":"10.1093\/neuonc\/noaa145"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Paramasivam G. Micro-RNA (miRNA): a biomarker to identify novel compounds in drug discovery and delivery for cancer therapy. Curr Drug Discov Technol. 2021;18 (6):e130921188092.","DOI":"10.2174\/1570163817999201117114237"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mahernia S, Hassanzadeh M, Adib M, et al. The possible effect of microRNA-155 (miR-155) and BACE1 inhibitors in the memory of patients with down syndrome and Alzheimer&apos;s disease: design, synthesis, virtual screening, molecular modeling and biological evaluations. J Biomol Struct Dyn. 2022;40 (13):5803-14. Epub 2021 Jan 22.","DOI":"10.1080\/07391102.2021.1873861"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Keck-Wherley J, Grover D, Bhattacharyya S, et al. Abnormal microRNA expression in Ts65Dn hippocampus and whole blood: contributions to Down syndrome phenotypes. Dev Neurosci. 2011;33 (5):451-67.","DOI":"10.1159\/000330884"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Pedersen IM, Otero D, Kao E, et al. Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol Med. 2009;1 (5):288-95.","DOI":"10.1002\/emmm.200900028"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/90\/4\/90_JNMS.2023_90-502\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:12:36Z","timestamp":1715577156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/90\/4\/90_JNMS.2023_90-502\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2023_90-502","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"article-number":"JNMS.2023_90-502"}}